{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T23:16:44Z","timestamp":1769555804501,"version":"3.49.0"},"reference-count":19,"publisher":"Japanese Society of Internal Medicine","issue":"15","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2016]]},"DOI":"10.2169\/internalmedicine.55.6448","type":"journal-article","created":{"date-parts":[[2016,7,31]],"date-time":"2016-07-31T22:08:26Z","timestamp":1470002906000},"page":"2011-2017","source":"Crossref","is-referenced-by-count":10,"title":["Onset of Tuberculosis from a Pulmonary Latent Tuberculosis Infection during Antiviral Triple Therapy for Chronic Hepatitis C"],"prefix":"10.2169","volume":"55","author":[{"given":"Shunichi","family":"Matsuoka","sequence":"first","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirotoshi","family":"Fujikawa","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Japan Community Health Care Organization Yokohama Central Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromasa","family":"Hasegawa","sequence":"additional","affiliation":[{"name":"Department of Oral Pathology, Matsumoto Dental University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takanaga","family":"Ochiai","sequence":"additional","affiliation":[{"name":"Department of Oral Pathology, Matsumoto Dental University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukinobu","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuhiko","family":"Moriyama","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 368: 1867-1877, 2013.","DOI":"10.1056\/NEJMoa1214854"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Lawitz E, Poordad FF, Pang PS, et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet 383: 515-523, 2014.","DOI":"10.1016\/S0140-6736(13)62121-2"},{"key":"3","doi-asserted-by":"publisher","unstructured":"3. Liaw YF, Jia JD, Chan HL, et al. Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C. Hepatology 54: 1591-1599, 2011.","DOI":"10.1002\/hep.24555"},{"key":"4","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1016\/S0140-6736(07)61904-7","volume":"370","author":"B Escudier","year":"2007","unstructured":"4. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370: 2103-2111, 2007.","journal-title":"The Lancet","ISSN":"https:\/\/id.crossref.org\/issn\/0140-6736","issn-type":"print"},{"key":"5","doi-asserted-by":"publisher","unstructured":"5. Hu KQ, Tong MJ. The long-term outcomes of patients with compensated hepatitis C virus-related cirrhosis and history of parenteral exposure in the United States. Hepatology 29: 1311-1316, 1999.","DOI":"10.1002\/hep.510290424"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Kumada H, Toyota J, Okanoue T, et al. Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan. J Hepatol 56: 78-84, 2012.","DOI":"10.1016\/j.jhep.2011.07.016"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Komiya K, Ariga H, Nagai H, et al. Impact of peripheral lymphocyte count on the sensitivity of 2 IFN-Y release assays, QFT-G and ELISPOT, in patients with pulmonary tuberculosis. Inter Med 49: 1849-1855, 2010.","DOI":"10.2169\/internalmedicine.49.3659"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Sabbatani S, Manfredi R, Marinacci G, et al. Reactivation of severe, acute pulmonary tuberculosis during treatment with pegylated interferon-alpha and ribavirin for chronic HCV hepatitis. Scand J Infect Dis 38: 205-208, 2006.","DOI":"10.1080\/00365540500263268"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Belkahla N, Kchir H, Maamouri N, et al. Reactivation of tuberculosis during dual therapy with pegylated interferon and ribavirin for chronic hepatitis C. Rev Med Interne 31: e1-e3, 2010.","DOI":"10.1016\/j.revmed.2009.11.017"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Farah R, Awad J. The association of interferon with the development of pulmonary tuberculosis. Int J Clin Pharmacol Ther 45: 598-600, 2007.","DOI":"10.5414\/CPP45598"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Yu ML, Dai CY, Lee LP, et al. Outcome of chronic hepatitis C patients who required early termination of pegylated interferon-alpha plus ribavirin combination therapy. Antivir Ther 11: 1015-1019, 2006.","DOI":"10.1177\/135965350601100814"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Rodr\u00edguez-Medina B, Blanes M, Vinaixa C, et al. Haemophagocytic syndrome in a liver transplant patient during treatment with Telaprevir. Ann Hepatol 12: 974-978, 2013.","DOI":"10.1016\/S1665-2681(19)31305-5"},{"key":"13","doi-asserted-by":"publisher","unstructured":"13. Shibata M, Morizane T, Uchida T, et al. Irregular regeneration of hepatocytes and risk of hepatocellular carcinoma in chronic hepatitis and cirrhosis with hepatitis-C-virus infection. Lancet 351: 1773-1777, 1998.","DOI":"10.1016\/S0140-6736(97)08002-1"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Matsumura H, Nirei K, Nakamura H, et al. Histopathology of type C liver disease for determining hepatocellular carcinoma risk factors. World J Gastroenterol 19: 4887-4896, 2013.","DOI":"10.3748\/wjg.v19.i30.4887"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Gaya DR, Thorburn D, Oien KA, et al. Hepatic granulomas: a 10 year single centre experience. J Clin Pathol 56: 850-853, 2003.","DOI":"10.1136\/jcp.56.11.850"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Uchida T, Taira M, Shikata T, et al. Histological difference between complete responders and non-responders to interferon therapy of the livers of patients with chronic hepatitis C. Acta Pathol Jpn 43: 230-236, 1993.","DOI":"10.1111\/j.1440-1827.1993.tb01137.x"},{"key":"17","unstructured":"17. Rajan A, Kar P. Hepatic granulomatosis. J Assoc Physicians India 51: 289-296, 2003."},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Drebber U, Kasper HU, Ratering J, et al. Hepatic granulomas: Histological and molecular pathological approach to differential diagnosis-a study of 442 cases. Liver Int 28: 828-834, 2008.","DOI":"10.1111\/j.1478-3231.2008.01695.x"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Babudieri S, Soddu A, Murino M, et al. Tuberculosis screening before anti-hepatitis c virus therapy in prisons. Emerg Infect Dis 18: 689-691, 2012.","DOI":"10.3201\/eid1804.111016"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/55\/15\/55_55.6448\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,4]],"date-time":"2022-07-04T13:37:16Z","timestamp":1656941836000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/55\/15\/55_55.6448\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":19,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.55.6448","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016]]}}}